Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PURPOSE: Omega-3 Fatty Acids for Psychosis Prevention in UHR Subjects
NCT02597439Phase 4Completed
- Start
- Sep 2016
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 4 trial of omega-3 fatty acid in psychosis. Started Sep 2016; status: completed.
02
Drugs
omega-3 fatty acid
03
Conditions
psychosis
Beyond the preview
Go deeper on NCT02597439.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597439.